Study to Evaluate the Combination of Enteric-coated Mycophenolate Sodium (EC-MPS), Basiliximab, and C2-monitored Cyclosporine in de Novo Renal Transplant Recipients at Potential High Risk of Delayed Graft Function (DGF)

NCT00154232 | Completed Phase 4

• 1 other identifier: CERL080AAR01
• Study Type: interventional
• Target: 46
• Locations: 0 countries
• Sites: N/A

Brief Summary

The aim of the study is to assess the short-term benefit of the combination of basiliximab, EC-MPS and cyclosporine microemulsion with C2 monitoring on the prophylaxis of acute rejection in a population of de novo renal transplant patients at potential high risk of DGF.

Conditions

Renal Transplantation

Keywords

Renal transplantation, DGF, basiliximab, EC-MPS, cyclosporine

Outcome Measures

Primary Outcomes (1)

• Incidence of first episodes of BPAR at month 3 post transplant

Secondary Outcomes (7)

• Incidence of patients death at month 3 post transplant.

• Incidence of graft loss or, synonymously, graft failure)

• The allograft will defined as lost (or: to have failed)

• when the patient begins dialysis treatments without

• subsequent graft recovery.

Interventions

Enteric-Coated Mycophenolate Sodium (EC-MPS) DRUG

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• \- Age 18-70 years old
• Patients receiving a primary or secondary cadaveric or living donor kidney
• Patients who have given written informed consent for study participation
• Females capable of becoming pregnant must have a negative pregnancy test at baseline and are required to practice birth control for the duration of the study and at least for four months following the last dose of basiliximab.

You may not qualify if:

• Recipient of multi-organ transplants or previously transplanted organs other than kidney
• Recipient of dual kidney transplants
• Recipient of a transplanted kidney from a Non-Heart Beating Donor (NHBD)
• Recipient of a HLA identical living-donor kidney
• Patients with a PRA level (past or current level) greater than 20%
• Patients anticipated by investigators to require induction therapy with OKT3, ATGAM, or Thymoglobulin for any reason
• Patients with any medical condition which, in the opinion of the investigator, would preclude the patient from participating in the study
• Cold ischemia time larger than 36 hours.
• Patients who have received an investigational drug or therapy within one month prior to study entry or if such therapy is to be instituted post-transplantation.
• Female transplant candidates who are pregnant, lactating, or of childbearing potential and not willing to practice an acceptable method of contraception
• Patients with a known hypersensitivity to cyclosporine
• Patients with a known malignancy or a history of malignancy, other than successfully treated non-metastatic basal or squamous cell carcinoma of the skin
• Known HIV positive antibody status
• Evidence of any clinically relevant (per investigator determination) active infection
• Patients unable to participate in the study for the full 3-month study period

Sponsors & Collaborators

• Novartis Pharmaceuticals: lead

Study Officials

• Novartis

  Novartis

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 7, 2005
• First Posted: September 12, 2005
• Study Start: June 1, 2004
• Primary Completion: March 1, 2005
• Last Updated: November 2, 2011

Record last verified: 2011-11